Kelly Deck
CIK: 0001819427
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
INBX
Inhibrx Biosciences, Inc.
Officer
Discretionary Trading P&L
Holdings
About Deck Kelly
Deck Kelly (SEC CIK 0001819427) files insider reports with the SEC as Chief Financial Officer of Inhibrx Biosciences, Inc. (INBX).
Signal8 holds 1 ownership filing by Deck Kelly, a Form 4, filed on Apr 2, 2025. Those filings report 1 transaction, the latest on Apr 1, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Deck Kelly's filings is in LA JOLLA, CA.
Recent filings by Deck Kelly
- Apr 1, 2025: Grant or award of INBX derivative securities (Form 4, code A).
Other insiders filing for Inhibrx Biosciences, Inc. (INBX)
- Lappe Mark, Chief Executive Officer
- Kayyem Jon Faiz, Director
- FORSYTH DOUGLAS, Director
- Vuori Kristiina MD, Director
- MANHARD KIMBERLY, Director
- Matly David, President